Dave Manku

Dave Manku is a life-sciences consulting executive, not a traditional professional investor. He is a co-founder of BioSPEQ, Inc., a full-service consulting firm serving the biotech/pharmaceutical, medical device, and food/cosmetics industries. BioSPEQ merged with Azzur Group in 2014, and Manku became a Managing Partner of Azzur Group while continuing to lead the BioSPEQ business as its President. He brings more than 20 years of experience consulting in FDA-regulated and water-treatment industries, with expertise spanning engineering, validation, continuous improvement, and pharmaceutical manufacturing compliance.

Prior to founding BioSPEQ, Manku's career included roles associated with Prolacta Bioscience and Baxter International Inc., according to professional-profile aggregators. He is based in the Azusa/Irvine, California area.

Manku was educated at the University of Ottawa, where he earned undergraduate degrees in Biochemistry and Chemical Engineering and a Master of Engineering degree in Chemical Engineering. He has authored technical guidance content on building good-manufacturing-practice (GMP) foundations "from R&D to production" for industry outlets such as *Research & Development World*.

Azzur Group, the firm where Manku is a Managing Partner, was founded in 2010 and is headquartered in Hatboro, Pennsylvania. It provides consulting, facility solutions, engineering, validation, IT, technical, training, and laboratory services to life-sciences companies across the U.S.

• Note on the "angel investor / seed" classification: The label of "Angel Investor," "Director," and "Seed Round" in the source stub appears to originate from an investor-database aggregation rather than from documented, verifiable investing activity. No publicly verifiable record of angel or seed-stage investments by Dave Manku was found. His public professional identity is as a founder and operating partner in a life-sciences consulting firm.
• Where any investing or advisory interest would plausibly lie, it aligns with his domain: FDA-regulated life sciences — biotech/pharma, medical device, and food/cosmetics manufacturing and compliance.
• His demonstrated value-add to early-stage life-sciences companies is operational: GMP/quality systems, validation, regulatory readiness, and scale-up from R&D to production — the kind of hands-on expertise an operator-angel typically contributes alongside (or instead of) capital.